Last mentioned: Feb 19, 2026
Investors are bracing for pivotal Q4 2025 earnings reports from amusement park giant Six Flags (Legacy Cedar Fair) and biotech firm Insmed. While Six Flags navigates the complexities of its recent mega-merger, Insmed is focused on the commercial scaling of its lead therapy and the regulatory path for its pipeline.
This page surfaces every story mentioning Insmed across our finance coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running finance beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Insmed was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |